In Brief SARS-CoV-2’s rapid global spread exposed PCR testing limitations. We addressed this through mass spectrometry, developing a proteomics workflow targeting nucleocapsid protein peptides. By developing a selective MRM3 strategy, we achieved higher sensitivity compared to conventional methods. Our first approach detected viral peptides in nasopharyngeal samples with a cycle threshold (Ct) value down to 35 with sensitivity and specificity of 94.2% and 100.0% specificity without immunopurification. Subsequent mass spectrometry iterations, capable of processing 400+ samples daily, demonstrated 99.9% specificity and 93.1% sensitivity.
All Keywords
【저자키워드】 SARS-CoV-2, mass spectrometry, diagnostic test, high-throughput proteomics, clinical validation,
【저자키워드】 SARS-CoV-2, mass spectrometry, diagnostic test, high-throughput proteomics, clinical validation,